| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 01/29/2004 | WO2004009558A2 Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations |
| 01/29/2004 | WO2004009550A1 Piperidine derivatives and their use as selective inhibitors of mip-1alpha binding to its receptor ccr1 |
| 01/29/2004 | WO2004009547A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 01/29/2004 | WO2004009546A1 Indoline derivatives substituted in position 6, production and use thereof as medicaments |
| 01/29/2004 | WO2004009538A1 Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents |
| 01/29/2004 | WO2004009536A1 Novel compounds as histone deacetylase inhibitors |
| 01/29/2004 | WO2004009521A1 Remedy |
| 01/29/2004 | WO2004009131A1 Tumor treating combinations, compositions and methods |
| 01/29/2004 | WO2004009130A1 Tumor treating composition and methods |
| 01/29/2004 | WO2004009127A1 Localized delivery system for phenstatin using n-isopropylacrylamide |
| 01/29/2004 | WO2004009123A2 Gastrointestinal delivery of genetic material coupled to a transporting agent |
| 01/29/2004 | WO2004009112A1 Use of urease for inhibiting cancer cell growth |
| 01/29/2004 | WO2004009106A1 Preparation extracted from stephania tetrandra s. moor and the use thereof |
| 01/29/2004 | WO2004009089A1 Enhancing the effect of radioimmunotherapy in the treatment of tumors |
| 01/29/2004 | WO2004009088A1 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer |
| 01/29/2004 | WO2004009087A1 4-4(methylpiperazin-1-ylmethyl)-n-[4-methyl-3-(pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating mutated-ret kinase associated diseases |
| 01/29/2004 | WO2004009083A1 Antitumor compound and therapeutic uses thereof |
| 01/29/2004 | WO2004009081A1 Use of neomycin in the preparation of medicaments that are used in the treatment of diseases caused by hyperactivation of kinase proteins activated by mitogens (mapk) or by transcription factors |
| 01/29/2004 | WO2004009076A1 Paclitaxel composition for the intravesical treatment of bladder tumor and preparation method thereof |
| 01/29/2004 | WO2004009075A1 Composition for solubilization of paclitaxel and preparation method thereof |
| 01/29/2004 | WO2004009072A2 Tetrapropylammonium tetrathiomolybdate and related compounds for anti-angiogenic therapies |
| 01/29/2004 | WO2004009065A1 Hypoglycemic agent, liver protecting agent and anticancer agent containing lignans originating in hongdoushan |
| 01/29/2004 | WO2004009061A2 Bioavailability/bioefficacy enhaning activity of cuminum cyminum and extracts and fractions thereof |
| 01/29/2004 | WO2004009030A2 Angiogenesis inhibition by cephalotaxine alkaloids, derivatives, compositions and uses thereof |
| 01/29/2004 | WO2003101996A3 Esters in position 20 of camptothecins |
| 01/29/2004 | WO2003090664A3 Mutated hpv-16 e7 polypeptide, pharmaceutical composition comprising it and its preparation process |
| 01/29/2004 | WO2003061566A3 Anti-cancer combination and use thereof |
| 01/29/2004 | WO2003053366A3 Pyrimidine a2b selective antagonist compounds, their synthesis and use |
| 01/29/2004 | WO2003047634A3 Nucleic acids and methods for treating ebv-positive cancers |
| 01/29/2004 | WO2003042172A3 C-5 modified indazolylpyrrolotriazines |
| 01/29/2004 | WO2003040080A3 Lipoxin a4 analogs |
| 01/29/2004 | WO2003038113A3 Methods and compositions for the treatment and diagnosis of cellular proliferation disorders using 25943 |
| 01/29/2004 | WO2003037912A3 Tri-, tetra-, and penta-peptides having antiangiogenic activity |
| 01/29/2004 | WO2003032905A3 Preparation and use of carbohydrate-based ring structures with antimicrobial and cytostatic activity |
| 01/29/2004 | WO2003018014A3 Methods of inhibiting formation of vascular channels and profileration using pyridinone derivatives |
| 01/29/2004 | WO2003002137A3 Trp1, mct, or ftz-f1 homologous proteins involved in the regulation of energy homeostasis |
| 01/29/2004 | WO2003000194A3 Thienopyridine and thienopyrimidine anticancer agents |
| 01/29/2004 | WO2003000180A3 Dipeptidyl peptidase inhibitors for the treatment of diabetes |
| 01/29/2004 | WO2002099060A3 Dgks as modifiers of the p53 pathway and methods of use |
| 01/29/2004 | WO2002072794A3 Immunoglobulin superfamily proteins |
| 01/29/2004 | WO2002064014A9 Endomural therapy |
| 01/29/2004 | WO2002038106A3 Calcilytic compounds |
| 01/29/2004 | US20040019919 Calsyntenin-1-3 proteins, predominantly expressed in the nervous system , useful for the screening and for the preparation of a medicament for the treatment of nervous system disorders, most preferably brain |
| 01/29/2004 | US20040019232 Analogs of phosphonate and bisphosphonate compounds based on bone resorption suppressors (alendronic acid), viricides (cidofovir) and antineoplastic agents (bemcitabine); nontoxic; bioavailability; side effects reduction |
| 01/29/2004 | US20040019227 Aminoflavone compounds, compositions, and methods of use |
| 01/29/2004 | US20040019210 Kinase inhibitors |
| 01/29/2004 | US20040019201 Refluxing tetracyanoethylene oxide with tetraphenylporphyrin to form (5,10,15,20-tetraphenyl-2,3-(3'-dicyano)cyclopropano -2,3-chlorin); macromolecule intermediates used as chelate compounds; photosensitivity |
| 01/29/2004 | US20040019111 A new use of existing pharmaceutical, a nonsteroidal antiinflammatory agents |
| 01/29/2004 | US20040019103 Method of enhancing cellular production of molecular chaperon, hydroxylamine derivatives useful for enhancing the chaperon production and the preparation thereof |
| 01/29/2004 | US20040019102 Administering a thiuram disulfide and a heavy metal ion; activated transcription factor/adenosine cyclic phosphate response element binding protein (atf/creb) |
| 01/29/2004 | US20040019095 N, N'-dimethylated N-confused porphyrins |
| 01/29/2004 | US20040019093 Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them |
| 01/29/2004 | US20040019088 Use of Epothilones in the treatment of brain diseases associated with proliferative processes |
| 01/29/2004 | US20040019084 Nitric oxide synthase inhibitors; antioxidant regenerants |
| 01/29/2004 | US20040019083 Amino acid derivatives; antineoplastic agents |
| 01/29/2004 | US20040019078 Substituted tetrahydroisoquinoline compounds, methods of making, and their use |
| 01/29/2004 | US20040019077 Heterocyclic imines such as N1-(8-sulfonamide-5-isoquinoline)-N2-(3,3-diphenyl-2-propenyl) -ethylenediamine, used for prophylaxis and diagnosis of cancers, diabetes, cardiovascular and nervous system disorders, autoimmune diseases or obesity |
| 01/29/2004 | US20040019072 Dimer-selective RXR modulators and methods for their use |
| 01/29/2004 | US20040019065 Indolyl-urea derivatives of thienopyridines useful as antiangiogenic agents, and methods for their use |
| 01/29/2004 | US20040019063 Nitrogen compounds such as 4-(7-Hydroxy-1,3-dioxo-tetrahydro-pyrrolo(1,2-c)imidazol-2-yl)-5,6,7,8-tetrahydronaphthalene-1-carbonitrile, used for prophylaxis of muscular disorders; aging |
| 01/29/2004 | US20040019060 Drugs such as 9-(3,5-dimethyl-1-piperazinyl)propyl)carbazole, used for modulating endothelial cell proliferation |
| 01/29/2004 | US20040019059 Drugs such as N-(4-benzoylphenyl)-4,5-dihydro-3-(3-pyridinyl)-5-isoxazolecarboxamide, used as antiinflammatory or antiarthritic agents |
| 01/29/2004 | US20040019056 Anititumoral analogs of et-743 |
| 01/29/2004 | US20040019052 5-(2,3-Difluorophenyl)-1H-pyrazolo(3,4-c)pyridazin-3-ylamine, e.g.; an enzyme inhibitor of GSK-3, a serine/threonine protein kinase; neuroprotectants in treatment of acute stroke, neurotraumatic injuries and diabetic conditions |
| 01/29/2004 | US20040019048 Imidazo(4,5-c)quinoline and the 6,7,8,9-tetrahydro derivative having urea, thiourea, acylurea or sulfonylurea at the 1-position as immune response modifiers; biosynthesis of cytokines; viricides; antitumor, -carcinogenic agents |
| 01/29/2004 | US20040019046 Phenylacetamido-pyrazole derivatives and their use as antitumor agents |
| 01/29/2004 | US20040019045 Pyrazole compounds as anti-inflammatory and analgesic agents |
| 01/29/2004 | US20040019040 1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents |
| 01/29/2004 | US20040019037 E.g.,((5-(2,4-Diaminopyrimidin-6-yl)pentanoyl)-(N-methyl)amino )-3-(6-meth-oxypyridin-3-yl)-propanoic acid, inhibition of bone resorption, restenosis, angiogenesis inhibitors, antiarthritic, -tumor, -carcinogenic agents; antidiabetic |
| 01/29/2004 | US20040019036 Treating a related myeloproliferative disorder or a Ph-positive acute lymphocytic leukemia; able to induce or to improve hematologic response and/or cytogenetic response and, eventually, survival, with a mild non-hematologic toxicity |
| 01/29/2004 | US20040019035 3-(5,6,7,8-Tetrahydro-(1,8)naphthyridin-2-yl)-ethoxy)-11H-di-b enzo(1,4)oxazepin-10-yl)-acetic acid; inhibiting bone resorption; vascular restenosis; osteoporosis; angiogenesis inhibitors; diabetic retinopathy; anticarcinogenic agents |
| 01/29/2004 | US20040019016 Polycyclic compounds containing a central trivalent atom to which is attached either direct or indirectly via a linker a two or three ring system and a ring system contining sulphamate group as substituent; steroid sulfatase inhibitor |
| 01/29/2004 | US20040019015 Administering an effective amount of a protein tyrosine kinase inhibitor (containing first and second module) to the patient to protect against or to treat hearing loss |
| 01/29/2004 | US20040019011 Treatment of conitions and disease |
| 01/29/2004 | US20040019004 Anticancer agents; antitumor agents |
| 01/29/2004 | US20040019001 Modulation gene expression |
| 01/29/2004 | US20040018988 Camptothecin derivatives having antitumor activity |
| 01/29/2004 | US20040018987 Redox therapy for tumors |
| 01/29/2004 | US20040018972 Autoimmune diseases; antiallergens; rheumatic diseases; antiinflammatory agents |
| 01/29/2004 | US20040018968 Use of histone deacetylase inhibitors in combination with radiation for the treatment of cancer |
| 01/29/2004 | US20040018598 Chemical intermediate for discodermolide, epothilone |
| 01/29/2004 | US20040018571 PSCA: prostate stem cell antigen and uses thereof |
| 01/29/2004 | US20040018558 Method for identifying modulators of G protein coupled receptor signaling |
| 01/29/2004 | US20040018557 High speed elimination of immunoglobulins from human body |
| 01/29/2004 | US20040018525 Methods and compositions for the prediction, diagnosis, prognosis, prevention and treatment of malignant neoplasma |
| 01/29/2004 | US20040018516 Ixodes scapularis tissue factor pathway inhibitor |
| 01/29/2004 | US20040018508 Surrogate antibodies and methods of preparation and use thereof |
| 01/29/2004 | US20040018205 Mutated immunogenic peptides derived from R9M, polynucleotides coding for same and therapeutic uses thereof |
| 01/29/2004 | US20040018198 Antibodies against carbonic anydrase IX (CA IX) tumor antigen |
| 01/29/2004 | US20040018196 Proteins and nucleic acids encoding same |
| 01/29/2004 | US20040018194 Administering proteins that bind to CD30, or compete with monoclonal antibodies AC10 or HeFi-1 for binding to CD30, and exert a cytostatic or cytotoxic effect on Hodgkin's disease cells in the absence of effector cells or complement |
| 01/29/2004 | US20040018192 Integrin expression inhibitors |
| 01/29/2004 | US20040018191 Neutralizing human anti-IGFR antibody |
| 01/29/2004 | US20040018190 Drugs and foods improving the quality of life and process for producing the same |
| 01/29/2004 | US20040018184 Administering mixtures of monocytes and drugs selected from taxanes, alkaloids, antibiotics or enzyme inhibitors, as anticarcinogenic agents |
| 01/29/2004 | US20040018177 Vacination method |
| 01/29/2004 | US20040018171 Biochemical conjugates comprising tumor necrosis factor or interferons and ligands of CD antigen receptors, used as anticarcinogenic agents |
| 01/29/2004 | US20040018150 Screening prodrugs of methoxyphosphonate nucleotide analogues to identify prodrugs selectively targeting desired tissues with antiviral or antitumor activity. This method has led to the identification of novel mixed ester-amidates of PMPA for |
| 01/29/2004 | DE19964268B4 Verfahren zum Screenen einer Verbindung, welche die Wechselwirkung zwischen IGF-1R und einem der Polypeptide IIP-1 bis IIP-10 hemmt A method for screening a compound which inhibits the interaction between IGF-1R and IIP-one of the polypeptides 1 to IIP-10 |
| 01/29/2004 | DE10229778A1 Neue Verwendung von Imidazotriazinonen New use of imidazotriazinones |